Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants

NCT06921824 | Completed

• 1 other identifier: GluCoMet_stepwise glucagon
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants. Participants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.

Conditions

Glucose Metabolism; Glucagon

Outcome Measures

Primary Outcomes (1)

• Glucagon infusion rate that increases plasma glucose

  Glucagon infusion rate at which plasma glucose levels are significantly increased compared to baseline

  0-180 minutes

Secondary Outcomes (4)

• Glucagon infusion rate that increases plasma cAMP

  0-180 minutes

• Glucagon infusion rate that decreases plasma amino acids

  0-180 minutes

• Glucagon infusion rate that affects plasma triglycerides

  0-180 minutes

• Glucagon infusion rate that affects plasma nonesterified fatty acids

  0-180 minutes

Study Arms (1)

Glucagon Infusion

EXPERIMENTAL

Other: Glucagon

Interventions

Glucagon OTHER

A three-hour intravenous infusion with glucagon with increasing infusion rate (from 0,01 ng/kg/min up to 50 ng/kg/min)

Glucagon Infusion

Eligibility Criteria

• Age: 25 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Capable of understanding the participant information and signing the consent form
• Between 25 and 70 years of age at the time of screening
• Body mass index (BMI) ≤ 25 kg/m2 at the time of screening

You may not qualify if:

• Enrolment in other research projects that might interfere with the study
• Diabetes diagnosis (type 1 and 2)
• Pregnancy or breastfeeding
• Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
• Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
• Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female
• Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic
• Active or recent malignant disease
• Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
• Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol

Sponsors & Collaborators

• Nicolai Jacob Wewer Albrechtsen: lead

Study Sites (1)

Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark

Copenhagen, 2400, Denmark

Location

MeSH Terms

Interventions

Glucagon

Intervention Hierarchy (Ancestors)

Proglucagon; Pancreatic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Study Officials

• Nicolai J Wewer Albrecthsen, MD PhD

  Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 3, 2025
• First Posted: April 10, 2025
• Study Start: March 31, 2025
• Primary Completion: September 19, 2025
• Study Completion: September 19, 2025
• Last Updated: December 24, 2025

Record last verified: 2025-12

Locations

DK (1)